PUBLIC COMPANY
saveSHIONOGI
USupdated 1d ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke
- phase2A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease
- phase3Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis
- phase2Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke
- phase2Dose Finding Study of MCI-186 in Acute Ischemic Stroke
- phase1Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Subjects (Food Effect Study)
- phase1Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis
- phase1A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy Subjects
🐶 Hiring Signal
News
- Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOsSanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.biopharma_dive · 7h ago
- Apnimed’s IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launchApnimed has raised $192 million for its upsized IPO, with the proceeds earmarked to fund the launch of its sleep apnea pill.fiercebiotech · 18h ago
- Antifungal from F2G, Shionogi succeeds in Phase 3 studyF2G and Shionogi released positive Phase 3 data on Thursday morning, giving the companies a potentially clear path to approval for their antifungal drug. The companies said their treatment called o…endpoints · 1mo ago
- Shionogi wins US approval for first pill to prevent Covid following exposureJapan's Shionogi on Monday said it won FDA approval for its oral antiviral to prevent Covid‑19 in adults and children older than 12 years who have been in contact with someone ...endpoints · 2mo ago
comments(0)
5-min edit window · permanent after that